BridgeBio Pharma Inc

NASDAQ:BBIO   3:59:59 PM EDT
39.69
+0.03 (+0.08%)
Products

Bridgebio Pharma And Affiliate Origin Biosciences Says FDA Acceptance Of Its New Drug Application For Fosdenopterin For The Treatment Of Mocd Type A

Published: 09/29/2020 11:44 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma and Affiliate Origin Biosciences Announces FDA Acceptance of Its New Drug Application for Fosdenopterin for the Treatment of Mocd Type A.
Bridgebio Pharma Inc - Look Forward to Submitting Second NDA Later This Year for Infigratinib for Second Line Treatment of Cholangiocarcinoma.
Bridgebio Pharma Inc - NDA Has Been Granted Priority Review Designation.